Evidence map›Paper›PMID 31031980›Full record

ArticleMolecular and clinical oncology2019

Analysis of genes encoding epigenetic regulators in myeloproliferative neoplasms: Coexistence of a novel

Laura Eder-Azanza, Cristina Hurtado, David Navarro-Herrera, Diego Calavia, Francisco Javier Novo, José Luis Vizmanos

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. The impact of SETBP1 mutations in neurological diseases and cancer.Genes to cells : devoted to molecular & cellular mechanisms · 2023
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Laura Eder-AzanzaDepartment of Biochemistry and Genetics, School of Sciences, University of Navarra, E-31008 Pamplona, Spain.
Cristina HurtadoDepartment of Biochemistry and Genetics, School of Sciences, University of Navarra, E-31008 Pamplona, Spain.
David Navarro-HerreraDepartment of Biochemistry and Genetics, School of Sciences, University of Navarra, E-31008 Pamplona, Spain.
Diego CalaviaDepartment of Biochemistry and Genetics, School of Sciences, University of Navarra, E-31008 Pamplona, Spain.
Francisco Javier NovoDepartment of Biochemistry and Genetics, School of Sciences, University of Navarra, E-31008 Pamplona, Spain.
José Luis VizmanosDepartment of Biochemistry and Genetics, School of Sciences, University of Navarra, E-31008 Pamplona, Spain.
Universidad de Navarra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years it has been shown that the causes of chronic myeloproliferative neoplasms (MPNs) are more complex than a simple signaling aberration and many other mutated genes affecting different cell processes have been described. For instance, mutations in genes encoding epigenetic regulators are more frequent than expected. One of the latest genes described as mutated is

Indexed as

epigenetic regulatorsgenetic complexityJanus kinase 2primary myelofibrosisSET binding protein 1

Identifiers

PMID31031980
PMCPMC6482393
OpenAlexW2937755448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.